Amgen to acquire Oxford spinout Dark Blue, tucking in a preclinical cancer drug Endpoints NewsAmgen swoops on UK cancer biotech in deal worth up to $840mn Financial TimesAMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE PR NewswireAmgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs Fierce BiotechRecon: Amgen to acquire Dark Blue for $480M; CDC slashes recommendations for childhood vaccines Regulatory Affairs Professionals Society | RAPS
